Original Research ARTICLE
Development of a bispecific antibody targeting CD30 and CD137 for Hodgkin Lymphoma therapy
- 1National University of Singapore, Singapore
- 2Singapore Immunology Network (A*STAR), Singapore
Hodgkin Lymphoma (HL) is a malignancy that frequently affects young adults. Although there are effective treatments not every patient responds, necessitating the development of novel therapeutic approaches, especially for relapsed and refractory cases. The two TNF receptor family members CD30 and CD137 are expressed on Hodgkin and Reed Sternberg (HRS) cells, the malignant cells in HL. We found that this coexpression is specific for HRS cells. Based on this discovery we developed a bispecific antibody that binds preferentially to the CD30, CD137-double positive HRS cells. The CD30, CD137 bispecific antibody gets internalized into HRS cells opening up the possibility to use it as a carrier for a toxin. This antibody also induces antibody-dependent, cell-mediated cytotoxicity in CD30, CD137-double positive HRS cells. The enhances specificity of the CD30, CD137 bispecific antibody to HRS cells makes it a promising candidate for development as a novel HL treatment.
Keywords: Hodgkin Lmyphoma, CD30, CD137, bispecific antibodies, Immunothearpy
Received: 07 Jan 2019;
Accepted: 09 Sep 2019.
Copyright: © 2019 Rajendran, Li, Ng, Wong, Cheng, Wang and Schwarz. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Prof. Herbert Schwarz, National University of Singapore, Singapore, 119077, Singapore, firstname.lastname@example.org